News

ReAlta Life Sciences Announces Proof of Mechanism Data from the Phase 1b Inhaled LPS Trial of RLS-0071, Demonstrating Powerful Inhibition of Lung Neutrophils and Inflammatory Cytokines

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced exciting new proof-of-mechanism data from the company’s Phase 1b Inhaled LPS clinical trial of RLS-0071 presented at the American Thoracic Society International Conference on May 23, 2023. RLS-0071 is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for HIE and other rare diseases.

“We are excited to share these new data from our Phase 1b trial, which clearly demonstrates the ability of RLS-0071 to dramatically inhibit neutrophil infiltration and pro-inflammatory cytokines such as IL-1ß and IL-8 in a human model of LPS-initiated acute lung disease,” said Ulrich Thienel, Ph.D., M.D., chief executive officer of ReAlta. “The clear translatability of our mechanisms of action from preclinical models to humans encourages our efforts to explore RLS-0071 as a potential therapy for acute pulmonary diseases and other neutrophil-mediated disease processes.”

Findings from the Phase 1b Inhaled LPS trial demonstrated that treatment with RLS-0071 was safe and well-tolerated. Thirty subjects were randomized into three cohorts (10 subjects per cohort) that first inhaled lipopolysaccharide (LPS) and then received three administrations of RLS-0071 at 10 mg/kg (low dose), a 120 mg/kg loading dose followed by two administrations of 40 mg/kg (high dose) or placebo at 1 hour, 8 hours and 16 hours timepoints after the initial LPS inhalation. Blood and sputum were collected for analysis at 6-hour and 24-hour timepoints. Data presented at the American Thoracic Society (ATS) showed that:

RLS-0071 strongly inhibited neutrophil migration into the lungs by 50%

RLS-0071 showed statistically significant reductions in sputum neutrophils, sputum myeloperoxidase (MPO), sputum neutrophil elastase levels and NETosis markers

RLS-0071 also showed clear, meaningful reductions in IL- 1ß and IL-8 pro-inflammatory cytokines

The poster presentation given at ATS by Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine in Hannover, Germany and lead investigator for the study can be downloaded from the Our Science section of the ReAlta website. Based on the data from the Phase 1b Inhaled LPS trial, ReAlta plans further development in neutrophil-mediated pulmonary disease indications.

Learn more here.

Recent News

09/22/2023

State public health laboratory, Henrico County Schools launch pilot program to promote life science career

More than 50 Henrico County high school students and teachers joined scientists from Virginia’s public health and environmental laboratory Wednesday to kick off an innovative program that brings together private and government scientists and experts, business and nonprofit leaders, and public schools to explore ways to create a pipeline of talent to fuel Virginia’s growing

09/21/2023

Climate Tech Startup ThermaGEL Innovations’ Breakthrough Aerogels Join the Challenge to Save Half-Gigaton of C02 Emissions Each Year

In the fight against climate change, properly insulating homes and buildings can significantly raise energy efficiency and indoor air quality while lowering carbon dioxide emissions. A startup company, spun out of research at Virginia Commonwealth University, is commercializing what it calls a breakthrough in low-cost insulation materials. ThermaGEL Innovations has developed insulation material using aerogels,

09/20/2023

Charlottesville healthy sugar innovator Bonumose raises $2M

Bonumose Inc., a Charlottesville startup specializing in table sugar alternatives, has raised $2 million toward a $10 million funding round after German flavor and fragrances producer Symrise AG signed a minority investment agreement with the company. “The strategic investment from Symrise is part of a larger funding round that will be used for increasing sales,